HCV Policy & Advocacy
EASL 2014: WHO Recommends Global Use of Newest Hepatitis C Drugs, Urges Price Reductions
- Details
- Category: HCV Treatment Guidelines
- Published on Wednesday, 09 April 2014 00:00
- Written by Keith Alcorn
The World Health Organization has issued global treatment guidelines for hepatitis C, strongly recommending the use of the new direct-acting antivirals sofosbuvir (Sovaldi) with ribavirin for HCV genotypes 1, 2, 3, and 4, or simeprevir (Olysio) with pegylated interferon interferon and ribavirin for genotype 1 infection. The WHO guidelines were released to coincide with the 49th International Liver Congress this week in London. New guidelines from the European Association for the Study of the Liver (EASL) will be released on Saturday.
U.S. Government Releases Updated Viral Hepatitis Action Plan
- Details
- Category: HBV Policy & Advocacy
- Published on Tuesday, 08 April 2014 00:00
- Written by HIVandHepatitis.com
On April 3 the federal government released its latest 3-year update to the Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (initially launched in 2011), which provides a framework for strengthening the nation's response to hepatitis B and C.
IAS 2013: Experts Discuss Role of Drug Policy in HIV, Hepatitis, and TB Epidemics
- Details
- Category: People Who Inject Drugs
- Published on Tuesday, 02 July 2013 00:00
- Written by Liz Highleyman
International drug policy must shift from prohibition to public health in order to reduce harms to individuals and societies, including fueling the spread of HIV, hepatitis, and tuberculosis, experts from a range of disciplines agreed at 2 sessions held during the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
Doctors & Advocates Demand Better Health Coverage for HIV & Hepatitis
- Details
- Category: HIV Policy & Advocacy
- Published on Friday, 07 February 2014 00:00
- Written by HIVMA, AAHIVM and FPC
Coverage of preferred drugs in treatment guidelines, access to expert providers, lower co-pays, and clarity about patient assistance programs are among the steps HIV medical providers and patient advocates recommend to ensure that people with HIV and hepatitis C receive adequate care and treatment under the Affordable Care Act, according to separate statements released this week.
Antiretroviral PrEP Prevents HIV Transmission among Injection Drug Users
- Details
- Category: Injection Drug Use
- Published on Thursday, 13 June 2013 00:00
- Written by Liz Highleyman
Pre-exposure prophylaxis (PrEP) using daily oral tenofovir (Viread) reduced the risk of HIV acquisition among injection drug users in Thailand by half, according to findings from the Bangkok Tenofovir Study, published in the June 13, 2013, advance online edition of The Lancet. These findings led the CDC to recommend that PrEP be "considered as one of several prevention options for persons at very high risk for HIV acquisition" through injection drug use.
More Articles...
- War on Drugs Is Major Driver of Global Hepatitis C Epidemic
- EASL 2013: Compassionate Access to New Hepatitis C Drugs Is an 'Emergency' for European Patients
- EASL 2013: Triple-Drug HCV Therapy Comes with High Risk of Serious Adverse Events for Cirrhotics
- New Hepatitis C Helpline Offers Information and Referrals
Web Design and Development by